PE 22-28 and the TREK-1 channel research
Posted by optimizer_jenna in Research & News - 46 points, 4 comments.
I have been reading more about PE 22-28 lately since the discussions here about neuroplasticity have been so interesting. It is a synthetic peptide from spadin that targets the TREK-1 potassium channel. From what I can find in the preclinical data, it seems to work by increasing synaptogenesis and neurogenesis, which is quite different from how most antidepressants function.
Tbh, I am very skeptical about how quickly these results will translate to actual humans. The idea of a fast-acting antidepressant that works through TREK-1 blockade sounds amazing on paper, but since it is still in the preclinical stage, we really do not know the human safety profile or if the effects are actually sustainable. It feels a bit like the hype might outpace the actual science for a while. I am curious if anyone else is following the specific mechanism of TREK-1 inhibition or if you think the focus on neuroplasticity is being a bit overblown in the biohacking community.
I would love to see more actual human trials before I get too excited about it. Has anyone found any recent papers that discuss the specific safety concerns for this peptide?
Comments
- calm_ketogen: I agree with your skepticism, not gonna lie. People in this community love to jump from a mouse study to a human protocol in about five seconds. I have looked into the TREK-1 mechanism, and while the idea of blocking potassium channels to boost plasticity sounds interesting, we have no real idea how that affects a human brain over a long period. For me, the gap between preclinical data and a safe dose is usually huge. I have not seen any human safety papers yet. It feels like a lot of noise ri
- optimizer_jenna: I think you are right about people jumping to protocols too fast. Tbh, that is exactly why I am hesitant. I actually feel that the community is chasing the next big thing because the usual options can be so slow or have such bad side effects. Since we have no human safety papers as you mentioned, it is just guesswork. Do you know if there are any similar peptides that actually have human data already?
- greg_labrat: Tbh i’m not convinced the hype is justified. The jump from mouse neuroplasticity data to human antidepressant use feels huge, and i haven’t seen any safety data yet. Do you think people are just looking for a new option because the usual ones fall short for them?
- optimizer_jenna: I agree with you that the jump from mice is HUGE. That is exactly why I am hesitant. Tbh, I think you are right about people just wanting a new option. Many traditional medicines take weeks to work and have bad side effects. It makes people desperate for something that sounds fast. Do you know of any other peptides that target the TREK-1 channel, or is PE 22-28 actually the only one being discussed?
Community discussion - research and educational context only. Not medical advice.